Transparency comments through Nov. 6
This article was originally published in The Tan Sheet
Executive SummaryFDA accepts comments on its transparency initiative through Nov. 6, after which the Transparency Task Force will conduct its second public meeting. The agency's transparency Web site, which features a blog about the initiative, will operate while the comment docket is open. The task force consists of Principal Deputy Commissioner Josh Sharfstein, the directors of each of FDA's centers, acting Associate Commissioner for Regulatory Affairs Michael Chappell, acting Chief Counsel Michael Landa and acting Chief Scientist Jesse Goodman. Commissioner Margaret Hamburg appointed the task force to identify how to improve communication and better explain agency decisions (1"The Tan Sheet" June 8, 2009)
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.